2016 International Congress Archives - Page 48 of 207

Correlations among motor, cognitive, and neuropsychiatric symptoms in Parkinson’s disease without dementia

M. Gang, Y. Nishio, T. Baba, A. Takeda, E. Mori (Sendai, Japan)
Cortical and subcortical contribution in the production of reaching movements in Parkinson’s disease

A. Canessa, N.G. Pozzi, G. Arnulfo, J. Brumberg, F. Steigerwald, M.F. Ghilardi, J. Volkmann, I.U. Isaias (Wuerzburg, Germany)
Cortical atrophy in cognitively impaired Parkinson’s disease patients

M.M. Almuqbel, T.R. Melzer, D.J. Myall, M.R. MacAskill, L. Livingston, K. Wood, T.L. Pitcher, R.J. Keenan, J.C. Dalrymple-Alford, T.J. Andrson (Christchurch, New Zealand)
Cortical excitability in patients with Parkinson’s disease on levodopa carbidopa intestinal gel thereapy

S.D. Kim, S. Vucic, N. Mahant, M.C. Kiernan, V.S.C. Fung (Sydney, Australia)
Cortical grey matter atrophy in the motor system in Friedreich ataxia: The IMAGE-FRDA study

I. Harding, L. Selvadurai, L. Corben, M. Stagnitti, E. Storey, G. Egan, M. Delatycki, N. Georgiou-Karistianis (Melbourne, Australia)
Cortical impairment as marker of dementia risk in probable REM sleep behavior disorder in Parkinson’s disease

A.D. Santana-Vargas, H. Duran-Meza, J.D. Ramirez-Diossa, G.H. Terrazas Gonzalez, M. Lopez-Ruiz, G. Millan-Rosas, U. Jimenez-Correa (Mexico City, Mexico)
Cortical phase amplitude coupling (PAC) identifies patterns in clinical states of Parkinson’s disease (PD) using magnetoencephalography (MEG)

E. Peña, S.A. Mian, L. Rosedahl, F.A.I. Mohammed, T.M. Mohammad, M.D. Johnson, J.A. Bajwa (Minneapolis, MN, USA)
Cortical role in the freezing of gait in Parkinson’s disease

M. Mihara, H. Otomune, H. Fujimoto, K. Konaka, Y. Watanabe, H. Mochizuki (Suita, Japan)
Cortical thinning associated with mild cognitive impairment in Parkinson’s disease

S. Galantucci, F. Agosta, T. Stojkovic, I. Petrovic, E. Stefanova, E. Canu, M. Copetti, V.S. Kostic, M. Filippi (Milan, Italy)
Cortico-striatal functional connectivity in the premanifest and manifest period of Huntingtons disease measured with high-field functional magnetic resonance imaging

M. Kronenbuerger, J. Hua, C.A. Ross (Baltimore, MD, USA)